INTUNIV had total market sales of $804 million in the US, according to IMS data as of March 2015.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced the launch of the generic equivalent to INTUNIV (guanfacine) in 1 mg, 2 mg, 3 mg, and 4 mg dosages, in the US. Guanfacine extended-release tablets are a non-stimulant medication for the treatment of attention deficit hyperactivity disorder (ADHD) that can be used alone, or as an add-on to stimulant medications.
ADHD is the most common neurobehavioral disorder diagnosed in children in the US. ADHD affects 1 in 10 US children and half of these children are diagnosed by the age of six. “Guanfacine extended-release tablets join Teva’s current generic line of seven ADHD products,” said Teva president and CEO North America Generic Medicines Brendan O’Grady. “We recognize the need to make affordable generic treatment options available to patients with ADHD.”
INTUNIV had total market sales of $804 million in the US, according to IMS data as of March 2015.
Published by Globes [online], Israel business news - www.globes-online.com - on June 2, 2015
© Copyright of Globes Publisher Itonut (1983) Ltd. 2015